MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561366 | Name: PACA
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PACA, also known as N-Propargyl Caffe amide, potentiates NGF-induced neurite outgrowth and attenuates 6-hydroxydopamine neurotoxicity in neuronal culture. Insufficient production of nerve growth factor (NGF) is implicated in Parkinson's disease (PD).

Chemical Structure

PACA
PACA
CAS#1431724-30-9

Theoretical Analysis

MedKoo Cat#: 561366

Name: PACA

CAS#: 1431724-30-9

Chemical Formula: C12H11NO3

Exact Mass: 217.0739

Molecular Weight: 217.22

Elemental Analysis: C, 66.35; H, 5.10; N, 6.45; O, 22.10

Price and Availability

Size Price Availability Quantity
10mg USD 550.00 2 Weeks
25mg USD 950.00 2 Weeks
50mg USD 1,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PACA; N-Propargyl Caffeamide; N-propargyl Caffeate Amide;
IUPAC/Chemical Name
3-(3,4-Dihydroxyphenyl)-N-2-propyn-1-yl-2-propenamide
InChi Key
HLHSUNWAPXINQU-GQCTYLIASA-N
InChi Code
InChI=1S/C12H11NO3/c1-2-7-13-12(16)6-4-9-3-5-10(14)11(15)8-9/h1,3-6,8,14-15H,7H2,(H,13,16)/b6-4+
SMILES Code
O=C(NCC#C)/C=C/C1=CC=C(O)C(O)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
PACA, also known as N-Propargyl Caffeamide, potentiates NGF-induced neurite outgrowth and attenuates 6-hydroxydopamine neurotoxicity in neuronal culture.
In vitro activity:
This study discovered that PACA not only potentiated NGF-induced neurite outgrowth but also attenuated 6-hydroxydopamine (6-OHDA) neurotoxicity in dopaminergic PC12 cells and primary rat midbrain neurons. Importantly, specific HO-1 inhibitor SnPP diminished the neuroprotective and neuritogenic activities of PACA. Moreover, PACA attenuated 6-OHDA-induced production of neurotoxic reactive oxygen species and reactive nitrogen species. Reference: ACS Chem Neurosci. 2015 Sep 16;6(9):1560-9. https://pubmed.ncbi.nlm.nih.gov/26147318/
In vivo activity:
The aim of the present study was to investigate whether PACA could increase NGF levels against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) neurotoxicity in a mouse PD model. This study induced parkinsonism in mice by intraperitoneal injection of MPTP for seven consecutive days. Animal motor functions were assessed by rotarod test and pole test. The results showed that PACA ameliorated motor impairments in MPTP-challenged mice. Based on Western blot analysis and/or immunofluorescence staining of NGF and tyrosine hydroxylase (TH), PACA preserved TH levels in the midbrain substantia nigra pars compacta. PACA also increased NGF expression while it decreased proNGF accumulation. Reference: Mol Neurobiol. 2018 Mar;55(3):2258-2267. https://pubmed.ncbi.nlm.nih.gov/28321769/

Preparing Stock Solutions

The following data is based on the product molecular weight 217.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Cheng Y, Yang C, Luo D, Li X, Le XC, Rong J. N-Propargyl Caffeamide Skews Macrophages Towards a Resolving M2-Like Phenotype Against Myocardial Ischemic Injury via Activating Nrf2/HO-1 Pathway and Inhibiting NF-ĸB Pathway. Cell Physiol Biochem. 2018;47(6):2544-2557. doi: 10.1159/000491651. Epub 2018 Jul 11. PMID: 29996121. 2. Yang C, Zhao J, Cheng Y, Le XC, Rong J. N-Propargyl Caffeate Amide (PACA) Potentiates Nerve Growth Factor (NGF)-Induced Neurite Outgrowth and Attenuates 6-Hydroxydopamine (6-OHDA)-Induced Toxicity by Activating the Nrf2/HO-1 Pathway. ACS Chem Neurosci. 2015 Sep 16;6(9):1560-9. doi: 10.1021/acschemneuro.5b00115. Epub 2015 Jul 16. PMID: 26147318. 3. Cheng Y, Luo D, Zhao Y, Rong J. N-Propargyl caffeate amide (PACA) prevents cardiac fibrosis in experimental myocardial infarction by promoting pro-resolving macrophage polarization. Aging (Albany NY). 2020 Mar 23;12(6):5384-5398. doi: 10.18632/aging.102959. Epub 2020 Mar 23. PMID: 32203054; PMCID: PMC7138579. 4. Luo D, Zhao J, Cheng Y, Lee SM, Rong J. N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF. Mol Neurobiol. 2018 Mar;55(3):2258-2267. doi: 10.1007/s12035-017-0486-6. Epub 2017 Mar 21. PMID: 28321769.
In vitro protocol:
1. Cheng Y, Yang C, Luo D, Li X, Le XC, Rong J. N-Propargyl Caffeamide Skews Macrophages Towards a Resolving M2-Like Phenotype Against Myocardial Ischemic Injury via Activating Nrf2/HO-1 Pathway and Inhibiting NF-ĸB Pathway. Cell Physiol Biochem. 2018;47(6):2544-2557. doi: 10.1159/000491651. Epub 2018 Jul 11. PMID: 29996121. 2. Yang C, Zhao J, Cheng Y, Le XC, Rong J. N-Propargyl Caffeate Amide (PACA) Potentiates Nerve Growth Factor (NGF)-Induced Neurite Outgrowth and Attenuates 6-Hydroxydopamine (6-OHDA)-Induced Toxicity by Activating the Nrf2/HO-1 Pathway. ACS Chem Neurosci. 2015 Sep 16;6(9):1560-9. doi: 10.1021/acschemneuro.5b00115. Epub 2015 Jul 16. PMID: 26147318.
In vivo protocol:
1. Cheng Y, Luo D, Zhao Y, Rong J. N-Propargyl caffeate amide (PACA) prevents cardiac fibrosis in experimental myocardial infarction by promoting pro-resolving macrophage polarization. Aging (Albany NY). 2020 Mar 23;12(6):5384-5398. doi: 10.18632/aging.102959. Epub 2020 Mar 23. PMID: 32203054; PMCID: PMC7138579. 2. Luo D, Zhao J, Cheng Y, Lee SM, Rong J. N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF. Mol Neurobiol. 2018 Mar;55(3):2258-2267. doi: 10.1007/s12035-017-0486-6. Epub 2017 Mar 21. PMID: 28321769.
1: Luo D, Zhao J, Cheng Y, Lee SM, Rong J. N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP(+)-Induced Neurons via Promoting the Conversion of proNGF to NGF. Mol Neurobiol. 2017 Mar 21. doi: 10.1007/s12035-017-0486-6. [Epub ahead of print] PubMed PMID: 28321769. 2: Yang C, Zhao J, Cheng Y, Le XC, Rong J. N-Propargyl Caffeate Amide (PACA) Potentiates Nerve Growth Factor (NGF)-Induced Neurite Outgrowth and Attenuates 6-Hydroxydopamine (6-OHDA)-Induced Toxicity by Activating the Nrf2/HO-1 Pathway. ACS Chem Neurosci. 2015 Sep 16;6(9):1560-9. doi: 10.1021/acschemneuro.5b00115. Epub 2015 Jul 16. PubMed PMID: 26147318.

View History

EVT801

EVT801

New Featured